Chugai Pharmaceutical Co., Ltd. has a long history of research and development (R&D), with Japan-based drug manufacturing starting in 1927. Since then, Chugai Pharmaceutical Co., Ltd. has achieved a number of significant research milestones, including the launch of its first biopharmaceutical in 1990, starting a 30-year history in biopharmaceuticals. Following the alliance with Roche, Chugai Pharmaceutical Co., Ltd.’s three research bases in Japan along with its satellite research hubs, including Chugai Pharma Europe, have combined expertise with the Roche Group, to discover promising new drug candidates for unmet medical needs.
Chugai Pharmaceutical Co., Ltd. has outlined a basic policy for their mission in R&D, and the objective of the Chugai Group to generate a steady stream of innovative products to address unmet medical needs.
Our European R&D team is based at our London headquarters, Chugai Pharma Europe. As an integral member of the Chugai Pharmaceutical Co., Ltd. R&D function, we contribute to the planning of global development programmes and lead the execution of European clinical trials. Our team focus on the clinical development of Chugai Pharmaceutical Co., Ltd. origin products, working directly with external organisations and leading experts to conduct safe and effective clinical studies, and to provide European insights to the Global network. By planning, implementing, evaluating, and reporting translational research and early clinical development, we support early proof-of-concept Chugai Pharmaceutical Co., Ltd. origin projects, and connect them to late-stage development, as one Global team.
Chugai Europe works in partnership on products under development and those already available to the healthcare community.
C-GB-00000900 | Date of Preparation: November 2023